These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

221 related items for PubMed ID: 17917562

  • 1. Evidence of agomelatine's antidepressant efficacy: the key points.
    Eser D, Baghai TC, Möller HJ.
    Int Clin Psychopharmacol; 2007 Oct; 22 Suppl 2():S15-9. PubMed ID: 17917562
    [Abstract] [Full Text] [Related]

  • 2. Beyond the monoaminergic hypothesis: agomelatine, a new antidepressant with an innovative mechanism of action.
    Kasper S, Hamon M.
    World J Biol Psychiatry; 2009 Oct; 10(2):117-26. PubMed ID: 19255935
    [Abstract] [Full Text] [Related]

  • 3. The interaction between the internal clock and antidepressant efficacy.
    Racagni G, Riva MA, Popoli M.
    Int Clin Psychopharmacol; 2007 Oct; 22 Suppl 2():S9-S14. PubMed ID: 17917564
    [Abstract] [Full Text] [Related]

  • 4. Agomelatine: a novel mechanism of antidepressant action involving the melatonergic and the serotonergic system.
    San L, Arranz B.
    Eur Psychiatry; 2008 Sep; 23(6):396-402. PubMed ID: 18583104
    [Abstract] [Full Text] [Related]

  • 5. Melatonin receptor agonist agomelatine: a new drug for treating unipolar depression.
    Bourin M, Prica C.
    Curr Pharm Des; 2009 Sep; 15(14):1675-82. PubMed ID: 19442180
    [Abstract] [Full Text] [Related]

  • 6. Agomelatine beyond borders: current evidences of its efficacy in disorders other than major depression.
    De Berardis D, Fornaro M, Serroni N, Campanella D, Rapini G, Olivieri L, Srinivasan V, Iasevoli F, Tomasetti C, De Bartolomeis A, Valchera A, Perna G, Mazza M, Di Nicola M, Martinotti G, Di Giannantonio M.
    Int J Mol Sci; 2015 Jan 05; 16(1):1111-30. PubMed ID: 25569089
    [Abstract] [Full Text] [Related]

  • 7. Agomelatine: innovative pharmacological approach in depression.
    Popoli M.
    CNS Drugs; 2009 Jan 05; 23 Suppl 2():27-34. PubMed ID: 19708723
    [Abstract] [Full Text] [Related]

  • 8. Agomelatine, an innovative pharmacological response to unmet needs.
    Le Strat Y, Gorwood P.
    J Psychopharmacol; 2008 Sep 05; 22(7 Suppl):4-8. PubMed ID: 18753276
    [Abstract] [Full Text] [Related]

  • 9. Superior antidepressant efficacy results of agomelatine versus fluoxetine in severe MDD patients: a randomized, double-blind study.
    Hale A, Corral RM, Mencacci C, Ruiz JS, Severo CA, Gentil V.
    Int Clin Psychopharmacol; 2010 Nov 05; 25(6):305-14. PubMed ID: 20856123
    [Abstract] [Full Text] [Related]

  • 10. The mechanism, efficacy, and tolerability profile of agomelatine.
    MacIsaac SE, Carvalho AF, Cha DS, Mansur RB, McIntyre RS.
    Expert Opin Pharmacother; 2014 Feb 05; 15(2):259-74. PubMed ID: 24328686
    [Abstract] [Full Text] [Related]

  • 11. [Agomelatine: the first "melatoninergic" antidepressant].
    Bánki MC.
    Neuropsychopharmacol Hung; 2006 Oct 05; 8(3):105-12. PubMed ID: 17211046
    [Abstract] [Full Text] [Related]

  • 12. Agomelatine: mechanism of action and pharmacological profile in relation to antidepressant properties.
    Guardiola-Lemaitre B, De Bodinat C, Delagrange P, Millan MJ, Munoz C, Mocaër E.
    Br J Pharmacol; 2014 Aug 05; 171(15):3604-19. PubMed ID: 24724693
    [Abstract] [Full Text] [Related]

  • 13. Treating each and every depressed patient.
    Kennedy SH.
    J Psychopharmacol; 2008 Sep 05; 22(7 Suppl):19-23. PubMed ID: 18753279
    [Abstract] [Full Text] [Related]

  • 14. Innovation translates into antidepressant effectiveness.
    Goodwin GM.
    J Psychopharmacol; 2008 Sep 05; 22(7 Suppl):9-12. PubMed ID: 18753277
    [Abstract] [Full Text] [Related]

  • 15. Agomelatine, a melatonin agonist with antidepressant properties.
    Dubovsky SL, Warren C.
    Expert Opin Investig Drugs; 2009 Oct 05; 18(10):1533-40. PubMed ID: 19758108
    [Abstract] [Full Text] [Related]

  • 16. Addressing circadian rhythm disturbances in depressed patients.
    Lam RW.
    J Psychopharmacol; 2008 Sep 05; 22(7 Suppl):13-8. PubMed ID: 18753278
    [Abstract] [Full Text] [Related]

  • 17. [A comparative evaluation of the efficacy of valdoxan (agomelatine) in recurrent depression and bipolar affective disorder].
    Tiuvina NA, Smirnova VN.
    Zh Nevrol Psikhiatr Im S S Korsakova; 2012 Sep 05; 112(11 Pt 2):53-60. PubMed ID: 23257757
    [Abstract] [Full Text] [Related]

  • 18. Synergistic mechanisms involved in the antidepressant effects of agomelatine.
    Tardito D, Molteni R, Popoli M, Racagni G.
    Eur Neuropsychopharmacol; 2012 Sep 05; 22 Suppl 3():S482-6. PubMed ID: 22867907
    [Abstract] [Full Text] [Related]

  • 19. The effect of melatonergic and non-melatonergic antidepressants on sleep: weighing the alternatives.
    Pandi-Perumal SR, Trakht I, Srinivasan V, Spence DW, Poeggeler B, Hardeland R, Cardinali DP.
    World J Biol Psychiatry; 2009 Sep 05; 10(4 Pt 2):342-54. PubMed ID: 18609422
    [Abstract] [Full Text] [Related]

  • 20. The emerging role of melatonin agonists in the treatment of major depression: focus on agomelatine.
    De Berardis D, Di Iorio G, Acciavatti T, Conti C, Serroni N, Olivieri L, Cavuto M, Martinotti G, Janiri L, Moschetta FS, Conti P, Di Giannantonio M.
    CNS Neurol Disord Drug Targets; 2011 Feb 05; 10(1):119-32. PubMed ID: 20874703
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.